Assessment on adverse drug reactions (ADR) that directly affects the quality of life and mortality and an important part of the post-marketed reassessment are developing gradually in China. Many problems have been identified in clinical validity and safety for the authorized Chinese herbs. An effective and standardized system is needed in the post-marketed drug reassessment. Evidence-based drug evaluation, which mainly includes clinical epidemiology, systematic review and health technology, will be used to assess the clinical validity, safety and cost of post-marketed drug and play an important role in the process of modernization and internationalization of Chinese herbs.
This paper discusses the characteristics of pharmacoecomomics and its evaluation methods. After launching a drug to the market, a large amount of clinical use provides the opportunity to evaluate the effectiveness and adverse effects. The methods of economic evaluation in post-marketing pay more attention to the value-added pharmacoeconomics activities to maintain product status, such as risk-benefit analysis, drug reimbursement application and budget impact analysis, etc.